Targeted therapeutic nanoparticles

Inventors

Yeoman, Roy R. • Winchurch, Richard A.

Assignees

NANODERM SCIENCES Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-9694085-B2

Patent

Publication Date

2017-07-04

Expiration Date


Abstract

Disclosure of methods and compositions related to chemical conjugations to nanoparticles of polysaccharides cross-linked to poloxamers as well as nano-sized colloids comprised of polysaccharides and poloxamers. The nanoparticles may be produced by various methods including inverse miniemulsion polymerization processes which create nanogels of desired size, shape, and stability for controlled therapeutic drug delivery, imaging, and theragnostic applications.

Core Innovation

The invention relates to nanoparticle targeting molecules and polysaccharide–poly(epoxide) nanogels and nanoparticles formed from polymeric networks comprising first block copolymeric segments derived from epoxide monomers and second polymeric segments derived from polysaccharides. In particular embodiments, the epoxide-derived block copolymer segments include poloxamers and the polysaccharide segments include dextran, producing a polymeric network in which targeting and therapeutic functionality is built into the nanogel/nanoparticle structure.

Targeting agents are chemically attached to the polymeric network, and the targeting agents comprise polymyxin B. The medicament is covalently attached to the polymeric network and includes vancomycin, with additional embodiments describing chemically attached targeting agents and medicaments for targeted, thermally responsive, and biodegradable drug delivery and theragnostics.

The disclosure further describes polysaccharide–poloxamer nanogels and hydrogels in which polymyxin B is conjugated to dextran–poloxamer either pre-polymer or post-surface, followed by functionalization and cross-linking. Documented embodiments also include medicaments encapsulated within the hydrogel, optional association of a fluorescent biomarker or a radiotag biomarker, size-defined and functionalized nanogels/nanoparticles with average diameters of 20 to 250 nm, and examples of specific targeting constructs including polymyxin B–dextran–poloxamer conjugates for therapeutic and diagnostic uses.

Claims Coverage

The independent claim set centers on three inventive features: a polymeric network built from epoxide-derived block copolymeric segments and polysaccharide-derived segments, targeting agents chemically attached to the network comprising polymyxin B, and a medicament covalently attached to the network where the medicament is vancomycin. Dependent claims further refine the identity of the epoxide monomers and polysaccharides, add an average diameter range, allow medicaments to be encapsulated within the hydrogel, and optionally associate a fluorescent biomarker or a radiotag biomarker.

Block copolymeric and polysaccharide polymeric network

A nanoparticle targeting molecule comprising a polymeric network comprising a plurality of first block copolymeric segments derived from epoxide monomers and a plurality of second polymeric segments derived from polysaccharides.

Polymyxin B chemically attached to the polymeric network

Targeting agents chemically attached to the polymeric network, wherein the targeting agents comprise polymyxin B.

Vancomycin covalently attached to the polymeric network

A medicament covalently attached to the polymeric network, wherein the medicament is vancomycin.

Poloxamers as the epoxide-derived segments

The epoxide monomers are poloxamers.

Dextran as the polysaccharide segments

The polysaccharide is dextran.

Size-constrained nanoparticle targeting molecule

The nanoparticle targeting molecule has an average diameter within 20 to 250 nanometers.

Encapsulation of medicaments within the hydrogel

The nanoparticle targeting molecule further comprises medicaments encapsulated within the hydrogel.

Fluorescent or radiotag biomarker association

The biomarker is a fluorescent biomarker or a radiotag biomarker.

The claim coverage focuses on a nanoparticle targeting molecule with a dual-segment polymeric network derived from epoxide monomers and polysaccharides, with polymyxin B as the chemically attached targeting agent and vancomycin as the covalently attached medicament. Dependent claims narrow the network to poloxamers and dextran and add optional encapsulation, biomarker association, and a specified nanoparticle diameter range.

Stated Advantages

Targeted delivery and theragnostics using chemically attached targeting agents on the nanoparticle targeting molecule.

Thermally responsive and biodegradable drug delivery and theragnostics.

Support for diagnostic functionality via association with a fluorescent biomarker or a radiotag biomarker.

Controllable size and drug loading.

Safety and biodegradability rationale for the platform.

Documented Applications

Targeted antimicrobial delivery, including vancomycin medicament and antimicrobial targeting via polymyxin B, with documented antimicrobial delivery embodiments including siRNA targeting gram-negative genes such as LpxC.

Cancer theranostics, including EGFR monoclonal antibody-conjugated nanoparticles and related targeting and theranostic embodiments, including mention of triple negative breast cancer.

Macrophage delivery in tuberculosis using mannosylated dextran.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.